Table 1. Interactions between CTCs derived from metastatic PCa patients and E-selectin-coated microtube surfaces.

Patient No.	Sample No.	Rolling and Tethering	Stable Adhesion	Total	Clinical History at time of sample collection	Clinical Response at time of sample collection
1	*1	3	3	29	Bone and LN metastases following progression on docetaxel and investigational therapy currently on ketoconazole/hydrocortisone	Progression
1	2	1	3	10	Bone and LN metastases following progression on docetaxel and investigational therapy currently on ketoconazole/hydrocortisone	Progression
1	3	28	14	270	Bone and LN metastases following progression on hormonal therapy, docetaxel, and investigational therapy currently on abiraterone/prednisone	Progression
1	4	0	0	72	Bone and LN metastases following progression on docetaxel and abiraterone currently on carboplatin/paclitaxel	Responding
1	5	0	0	12	Bone and LN metastases following progression on docetaxel and abiraterone currently on carboplatin/paclitaxel	Responding
2	6	0	0	9	Bone and LN metastases treated previously with hormonal therapy and docetaxel on investigational therapy	Progression
2	7	0	0	4	Bone and LN metastases treated previously with hormonal therapy and docetaxel on investigational therapy	Progression
3	8	0	3	5	Bone metastases following multiple lines of hormonal therapy	Progression
3	9	0	0	9	Bone metastases following multiple lines of hormonal therapy on docetaxel	Responding
4	10	0	1	2	Bone, LN, liver and lung metastases previously treated with docetaxel and abiraterone currently on carboplatin/paclitaxel	Progression
5	11	0	0	9	LN metastases with progression on hormonal therapy	Progression
5	12	0	0	1	LN metastases with progression on hormonal therapy and docetaxel currently on abiraterone/prednisone	Responding
6	*13	40	0	166	bone metastases with progression on docetaxel and investigational therapies	Progression
6	14	0	3	6	bone metastases with progression on docetaxel, investigational therapies, and abiraterone	Progression
7	15	2	1	41	bone, LN, colon, and bladder metastases following hormonal and investigational therapy	Progression
7	16	0	0	2	bone, LN, colon, and bladder metastases following hormonal and investigational therapy, currently on docetaxel	Responding
8	*17	0	2	3	bones metastases previously treated with multiple lines of hormonal therapy	Progression
8	18	0	0	0	bones metastases previously treated with multiple lines of hormonal therapy, currently on docetaxel	Responding
9	19	0	0	0	bone metastases progressing on initial hormonal therapy	Progression
10	20	2	1	53	LN and liver metastases previously treated with docetaxel currently on abiraterone	Progression
11	*21	9	2	28	bone metastases previously treated with docetaxel, ketoconazole, and investigational therapy	Progression
12	*22	1	0	2	LN metastases previously treated investigational therapy and docetaxel, currently on enzalutamide	Progression
13	23	0	0	0	bone and LN metastases on leuprolide and bicalutamide	Progression
14	24	0	0	20	bone and lungs metastases previously treated with hormonal therapy	Progression
15	*25	0	0	10	bone, LN, bladder and lung metastases previously treated with investigational therapy and docetaxel	Progression
16	26	0	0	0	bone and LN metastases previously treated with investigational therapy and docetaxel	Progression
17	27	1	0	22	LN and bladder metastases previously treatd with ketoconazole, docetaxel, investigational therapy, currently on cabazitaxel	Progression

LN= lymph node; Total means all J591-labeled CTCs; *No anti-CD45 depletion performed

Any patient with a treatment regimen of chemotherapy and CYP17 had corticosteroids

See the methods section for anti-CD45 depletion technique